about
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis.Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levelsDifferences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitisFunctional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseEarly dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitisEndoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases
P50
Q48136341-CC4F771D-4B13-4564-926C-A645E3337F67Q48160962-227A782F-2413-4F5A-B52C-027E6E201BA7Q64326944-061EF11D-9015-4F9C-88A3-1A979AFF1E35Q90363676-C2FD9B48-EEC7-4943-BB96-6022A79287C0Q90618574-C093B7C6-1D95-4AF6-BD37-4FC7FE89C701Q91358802-5B7F6735-8832-483E-B710-8206BC1885E8Q92777942-4BEE8226-95EC-4553-80BC-4FB784BA7A39Q94486643-1C8F1799-1511-4310-B01F-B65D8A534003
P50
description
investigador
@es
researcher
@en
name
Carlos Taxonera
@en
type
label
Carlos Taxonera
@en
prefLabel
Carlos Taxonera
@en
P31
P496
0000-0001-9166-7350